RE:RE:RE:RE:new drugs, very strategicThose who make statements on posturing, are completely clueless on the pharmaceutical process. Critics who solely focus on short-term sales performance without considering the broader strategic value of intellectual property fail to grasp the fundamentals of how pharmaceutical companies are truly valued. Sales being delayed because they decided not to make an inferior generic product, is not a bad thing, especially in the eyes of pharma investors. Therefore, any moron who complains about sales has no understanding on how pharma companies are valued. Intellectual Property is what give pharma companies value. Generics are low budget low revenue and have no value. The pivot to making new drugs is a damn good move. Creating new drugs being the cause of this delay in sales, is fundamentally beneficial rather than a negative in any way. I don’t believe sales is going to move this stock to new highs, but their drug development pipeline will be what elevates this stock to new levels. This is no longer a resource company, they are full on pharma, which in the long run will outperform any resource stock. The fact that they have 5 new drugs, that are licensed in Canada, is significant. Let me repeat this THE FACT THAT THEY HAVE 5 NEW DRUGS LICENSED IN CANADA, IS SIGNIFICANT. Not Generics Folks!